These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8815836)

  • 1. [Anticoagulant therapy in pulmonary embolism].
    Charbonnier B; Pacouret G; Augusseau-Richard MP; Dessenne X; Pagot O
    Arch Mal Coeur Vaiss; 1995 Nov; 88(11 Suppl):1755-61. PubMed ID: 8815836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review).
    Counsell C; Sandercock P
    Stroke; 2002 Jul; 33(7):1925-6. PubMed ID: 12105377
    [No Abstract]   [Full Text] [Related]  

  • 3. New therapeutic options in DVT prophylaxis.
    Wille-Jørgensen P
    Orthopedics; 2000 Jun; 23(6 Suppl):s639-42. PubMed ID: 10875428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current status of anticoagulants].
    Oger E; Mottier D
    Presse Med; 2000 May 27-Jun 3; 29(19):1079-82. PubMed ID: 10874921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New antithrombotic agents for the prevention and treatment of deep vein thrombosis.
    Boneu B
    Haemostasis; 1996 Oct; 26 Suppl 4():368-78. PubMed ID: 8979141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Heparin-induced thrombopenia and thrombosis].
    Stöckli TC; Walther A; Görres G; Ritz R; Marbet GA
    Schweiz Med Wochenschr; 1996 Mar; 126(12):483-8. PubMed ID: 8650513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modern aspects of prophylaxis and therapy for venous thrombo-embolic disease.
    Bergqvist D
    Aust N Z J Surg; 1998 Jul; 68(7):463-8. PubMed ID: 9669358
    [No Abstract]   [Full Text] [Related]  

  • 9. Anticoagulation in continuous renal replacement therapy.
    Vargas Hein O; Kox WJ; Spies C
    Contrib Nephrol; 2004; 144():308-16. PubMed ID: 15264419
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin.
    Riess H; Becker LK; Melzer N; Harenberg J
    Blood Coagul Fibrinolysis; 2014 Dec; 25(8):838-44. PubMed ID: 25004024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulants: to bleed or not to bleed, that is the question.
    Da Silva MS; Sobel M
    Semin Vasc Surg; 2002 Dec; 15(4):256-67. PubMed ID: 12478500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing pulmonary embolism from presentation to extended treatment.
    Cohen AT; Dobromirski M; Gurwith MM
    Thromb Res; 2014 Feb; 133(2):139-48. PubMed ID: 24182642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis of venous thromboembolism in stroke patients.
    Turpie AG
    Semin Thromb Hemost; 1997; 23(2):155-7. PubMed ID: 9200340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparins versus unfractionated heparin in the treatment of deep vein thrombosis and pulmonary embolism.
    Merli GJ
    Am J Phys Med Rehabil; 2000; 79(5 Suppl):S9-16. PubMed ID: 10994898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anticoagulation in patients with venous thromboembolism].
    Rüfer A; Wuillemin WA
    Ther Umsch; 2003 Jan; 60(1):43-7. PubMed ID: 12638478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant treatment of deep vein thrombosis and pulmonary embolism.
    Tran H; McRae S; Ginsberg J
    Cardiol Clin; 2008 May; 26(2):235-50, vi-vii. PubMed ID: 18406997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.
    Laposata M; Green D; Van Cott EM; Barrowcliffe TW; Goodnight SH; Sosolik RC
    Arch Pathol Lab Med; 1998 Sep; 122(9):799-807. PubMed ID: 9740137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence of venous thromboembolism after treatment with unfractionated heparin.
    Sutton SK
    Ann Intern Med; 1996 Mar; 124(5):532. PubMed ID: 8602716
    [No Abstract]   [Full Text] [Related]  

  • 19. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
    Decousus H; Leizorovicz A; Parent F; Page Y; Tardy B; Girard P; Laporte S; Faivre R; Charbonnier B; Barral FG; Huet Y; Simonneau G
    N Engl J Med; 1998 Feb; 338(7):409-15. PubMed ID: 9459643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
    Büller HR; Davidson BL; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob G; van den Berg-Segers AE; Cariou R; Leeuwenkamp O; Lensing AW;
    N Engl J Med; 2003 Oct; 349(18):1695-702. PubMed ID: 14585937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.